Richard Tobin
Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 11 | 2026 | 765 | 2.210 |
Why?
| | Myeloid-Derived Suppressor Cells | 6 | 2025 | 78 | 2.190 |
Why?
| | Histocompatibility Antigens Class II | 7 | 2025 | 365 | 1.100 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 5 | 2024 | 36 | 0.870 |
Why?
| | Skin Neoplasms | 4 | 2024 | 806 | 0.840 |
Why?
| | Anus Neoplasms | 1 | 2024 | 33 | 0.800 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2024 | 39 | 0.790 |
Why?
| | Rectal Neoplasms | 1 | 2024 | 160 | 0.730 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 103 | 0.700 |
Why?
| | Tretinoin | 2 | 2023 | 115 | 0.700 |
Why?
| | Hematologic Neoplasms | 1 | 2024 | 170 | 0.680 |
Why?
| | Ipilimumab | 2 | 2019 | 44 | 0.580 |
Why?
| | Lymphocyte Activation | 5 | 2025 | 1137 | 0.560 |
Why?
| | Tumor Escape | 2 | 2017 | 50 | 0.520 |
Why?
| | Neoplasms | 3 | 2024 | 2954 | 0.470 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 200 | 0.460 |
Why?
| | B-Lymphocytes | 5 | 2025 | 887 | 0.440 |
Why?
| | Neurodegenerative Diseases | 2 | 2026 | 147 | 0.410 |
Why?
| | Lysophospholipids | 2 | 2026 | 80 | 0.410 |
Why?
| | T-Lymphocyte Subsets | 4 | 2024 | 416 | 0.380 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1998 | 0.370 |
Why?
| | Brain Injuries, Traumatic | 3 | 2024 | 466 | 0.350 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2026 | 931 | 0.320 |
Why?
| | Brain Injuries | 1 | 2014 | 499 | 0.290 |
Why?
| | Uveal Neoplasms | 2 | 2026 | 16 | 0.280 |
Why?
| | Pre-Eclampsia | 3 | 2017 | 206 | 0.280 |
Why?
| | Brain | 2 | 2026 | 2991 | 0.270 |
Why?
| | Spleen | 4 | 2022 | 503 | 0.270 |
Why?
| | Immunity, Innate | 3 | 2025 | 844 | 0.240 |
Why?
| | Phosphoric Diester Hydrolases | 1 | 2026 | 53 | 0.230 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 156 | 0.230 |
Why?
| | Genes, MHC Class II | 2 | 2017 | 77 | 0.230 |
Why?
| | Data Curation | 1 | 2026 | 21 | 0.230 |
Why?
| | Antigen Presentation | 2 | 2025 | 209 | 0.230 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2025 | 48 | 0.230 |
Why?
| | T-Lymphocytes | 4 | 2024 | 2012 | 0.230 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2025 | 41 | 0.220 |
Why?
| | Cerebrovascular Disorders | 1 | 2026 | 103 | 0.220 |
Why?
| | Toll-Like Receptor 9 | 1 | 2025 | 37 | 0.220 |
Why?
| | Mice, Transgenic | 2 | 2024 | 2134 | 0.220 |
Why?
| | Natural Language Processing | 1 | 2026 | 103 | 0.220 |
Why?
| | Cellular Microenvironment | 1 | 2025 | 94 | 0.220 |
Why?
| | Dementia | 2 | 2026 | 324 | 0.210 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2024 | 14 | 0.210 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2025 | 134 | 0.210 |
Why?
| | Cell Movement | 2 | 2025 | 951 | 0.210 |
Why?
| | Dasatinib | 1 | 2024 | 58 | 0.200 |
Why?
| | Pseudomonas Infections | 1 | 2025 | 229 | 0.200 |
Why?
| | Mucous Membrane | 1 | 2024 | 130 | 0.190 |
Why?
| | Neuroimaging | 1 | 2026 | 307 | 0.190 |
Why?
| | Nervous System Diseases | 1 | 2026 | 288 | 0.190 |
Why?
| | Interleukin-4 | 2 | 2014 | 207 | 0.190 |
Why?
| | Antigens, Neoplasm | 1 | 2024 | 271 | 0.190 |
Why?
| | Myocarditis | 1 | 2024 | 103 | 0.190 |
Why?
| | Tumor Microenvironment | 2 | 2025 | 747 | 0.190 |
Why?
| | Autophagy | 1 | 2025 | 290 | 0.190 |
Why?
| | Vagotomy | 1 | 2022 | 33 | 0.190 |
Why?
| | Mice, Inbred C57BL | 9 | 2026 | 6034 | 0.180 |
Why?
| | Animals | 21 | 2026 | 38107 | 0.180 |
Why?
| | Capillary Permeability | 2 | 2013 | 133 | 0.180 |
Why?
| | Antineoplastic Agents | 3 | 2024 | 2219 | 0.180 |
Why?
| | Humans | 27 | 2026 | 146342 | 0.180 |
Why?
| | Mice | 14 | 2026 | 18297 | 0.180 |
Why?
| | Lymphocytes | 2 | 2020 | 379 | 0.170 |
Why?
| | Macrophage Migration-Inhibitory Factors | 1 | 2020 | 12 | 0.160 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2024 | 677 | 0.150 |
Why?
| | Neutrophils | 1 | 2025 | 1133 | 0.150 |
Why?
| | Splenectomy | 1 | 2020 | 61 | 0.150 |
Why?
| | Killer Cells, Natural | 1 | 2023 | 481 | 0.150 |
Why?
| | Liver Neoplasms | 1 | 2026 | 776 | 0.150 |
Why?
| | Cytokines | 3 | 2016 | 2081 | 0.150 |
Why?
| | Renal Circulation | 1 | 2019 | 75 | 0.140 |
Why?
| | Signal Transduction | 7 | 2026 | 5246 | 0.140 |
Why?
| | Haploinsufficiency | 1 | 2019 | 53 | 0.140 |
Why?
| | Immunotherapy | 1 | 2024 | 671 | 0.140 |
Why?
| | Interleukin-10 | 2 | 2025 | 310 | 0.140 |
Why?
| | CTLA-4 Antigen | 1 | 2019 | 105 | 0.140 |
Why?
| | Lipopolysaccharides | 2 | 2019 | 861 | 0.140 |
Why?
| | Septins | 1 | 2018 | 43 | 0.130 |
Why?
| | Monocytes | 2 | 2020 | 538 | 0.130 |
Why?
| | Cell Line, Tumor | 5 | 2025 | 3545 | 0.130 |
Why?
| | Peritoneal Diseases | 1 | 2016 | 5 | 0.120 |
Why?
| | Inflammation | 5 | 2016 | 2919 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2021 | 237 | 0.120 |
Why?
| | Granulocytes | 1 | 2017 | 82 | 0.120 |
Why?
| | Histamine | 1 | 2016 | 52 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 992 | 0.120 |
Why?
| | Fas Ligand Protein | 2 | 2015 | 61 | 0.120 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 213 | 0.120 |
Why?
| | Disease Models, Animal | 5 | 2024 | 4580 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2025 | 1432 | 0.120 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 231 | 0.120 |
Why?
| | fas Receptor | 2 | 2015 | 91 | 0.120 |
Why?
| | Pancreatic Cyst | 1 | 2017 | 50 | 0.120 |
Why?
| | Scotland | 2 | 2026 | 54 | 0.120 |
Why?
| | Hepatic Encephalopathy | 1 | 2015 | 24 | 0.110 |
Why?
| | Homeostasis | 1 | 2019 | 646 | 0.110 |
Why?
| | Caspase 3 | 2 | 2013 | 240 | 0.110 |
Why?
| | Mast Cells | 1 | 2016 | 150 | 0.110 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2019 | 415 | 0.110 |
Why?
| | Microvessels | 2 | 2013 | 98 | 0.110 |
Why?
| | Receptors, Lysophosphatidic Acid | 2 | 2026 | 40 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 103 | 0.100 |
Why?
| | Endothelium, Vascular | 4 | 2014 | 952 | 0.100 |
Why?
| | Neuroimmunomodulation | 1 | 2014 | 67 | 0.100 |
Why?
| | Lyme Disease | 1 | 2015 | 58 | 0.100 |
Why?
| | Toll-Like Receptors | 2 | 2017 | 193 | 0.100 |
Why?
| | Male | 13 | 2026 | 73396 | 0.100 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2015 | 233 | 0.100 |
Why?
| | Adaptive Immunity | 1 | 2014 | 173 | 0.100 |
Why?
| | Staurosporine | 1 | 2013 | 22 | 0.100 |
Why?
| | bcl-X Protein | 1 | 2012 | 44 | 0.090 |
Why?
| | NF-kappa B | 1 | 2016 | 674 | 0.090 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2012 | 70 | 0.090 |
Why?
| | Immunologic Factors | 1 | 2014 | 244 | 0.090 |
Why?
| | Blood Pressure | 2 | 2019 | 1765 | 0.090 |
Why?
| | Fetal Blood | 1 | 2014 | 325 | 0.090 |
Why?
| | Dendritic Cells | 1 | 2015 | 509 | 0.080 |
Why?
| | Mice, Knockout | 3 | 2026 | 3125 | 0.080 |
Why?
| | Shock, Hemorrhagic | 1 | 2013 | 195 | 0.080 |
Why?
| | Apoptosis | 3 | 2015 | 2439 | 0.080 |
Why?
| | Aged | 5 | 2026 | 26432 | 0.080 |
Why?
| | Antihypertensive Agents | 1 | 2014 | 519 | 0.080 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2024 | 39 | 0.070 |
Why?
| | Infant, Premature | 1 | 2014 | 622 | 0.070 |
Why?
| | Female | 10 | 2026 | 79499 | 0.070 |
Why?
| | Fetal Growth Retardation | 1 | 2014 | 592 | 0.070 |
Why?
| | Middle Aged | 5 | 2026 | 36619 | 0.070 |
Why?
| | Inflammation Mediators | 3 | 2016 | 508 | 0.070 |
Why?
| | Rats | 4 | 2019 | 5586 | 0.060 |
Why?
| | Cells, Cultured | 4 | 2017 | 4118 | 0.060 |
Why?
| | Atrophy | 1 | 2026 | 199 | 0.060 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2025 | 115 | 0.060 |
Why?
| | Adenocarcinoma | 1 | 2012 | 927 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 2 | 2024 | 983 | 0.060 |
Why?
| | Survival Analysis | 2 | 2020 | 1378 | 0.050 |
Why?
| | Chromones | 1 | 2024 | 43 | 0.050 |
Why?
| | Presenilin-1 | 1 | 2024 | 34 | 0.050 |
Why?
| | Flow Cytometry | 3 | 2014 | 1163 | 0.050 |
Why?
| | Amyloid beta-Protein Precursor | 1 | 2024 | 64 | 0.050 |
Why?
| | Toll-Like Receptor 3 | 2 | 2014 | 29 | 0.050 |
Why?
| | Morpholines | 1 | 2024 | 130 | 0.050 |
Why?
| | Adult | 4 | 2024 | 41087 | 0.050 |
Why?
| | Azepines | 1 | 2024 | 104 | 0.050 |
Why?
| | Immune Tolerance | 1 | 2026 | 386 | 0.050 |
Why?
| | Sirolimus | 1 | 2025 | 282 | 0.050 |
Why?
| | Reactive Oxygen Species | 2 | 2019 | 610 | 0.050 |
Why?
| | Proteinuria | 2 | 2014 | 103 | 0.050 |
Why?
| | Meninges | 1 | 2024 | 54 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 25 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2025 | 693 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 190 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2023 | 162 | 0.050 |
Why?
| | Interleukin-2 | 1 | 2024 | 434 | 0.050 |
Why?
| | Pseudomonas aeruginosa | 1 | 2025 | 392 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 123 | 0.040 |
Why?
| | Thymus Gland | 1 | 2023 | 310 | 0.040 |
Why?
| | Vagus Nerve | 1 | 2022 | 92 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 330 | 0.040 |
Why?
| | Neoplasm Proteins | 1 | 2024 | 444 | 0.040 |
Why?
| | Epilepsy | 1 | 2026 | 400 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 447 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 678 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 2 | 2019 | 2537 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2026 | 8391 | 0.040 |
Why?
| | Artificial Intelligence | 1 | 2026 | 389 | 0.040 |
Why?
| | Nerve Degeneration | 1 | 2020 | 48 | 0.040 |
Why?
| | Gestational Age | 2 | 2014 | 990 | 0.040 |
Why?
| | Receptors, CCR | 1 | 2020 | 6 | 0.040 |
Why?
| | Platelet Count | 1 | 2020 | 95 | 0.040 |
Why?
| | Basophils | 1 | 2020 | 52 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 79 | 0.040 |
Why?
| | Cyclic N-Oxides | 1 | 2019 | 32 | 0.040 |
Why?
| | Nephrons | 1 | 2019 | 23 | 0.040 |
Why?
| | Parkinson Disease | 1 | 2026 | 614 | 0.040 |
Why?
| | Lung | 1 | 2013 | 4122 | 0.040 |
Why?
| | Spin Labels | 1 | 2019 | 60 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2020 | 321 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 355 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 853 | 0.040 |
Why?
| | Pancreaticoduodenectomy | 1 | 2020 | 149 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2020 | 149 | 0.030 |
Why?
| | Astrocytes | 1 | 2020 | 229 | 0.030 |
Why?
| | Vasoconstriction | 1 | 2019 | 216 | 0.030 |
Why?
| | Pregnancy | 3 | 2017 | 7230 | 0.030 |
Why?
| | Phenotype | 1 | 2026 | 3206 | 0.030 |
Why?
| | Alzheimer Disease | 1 | 2024 | 641 | 0.030 |
Why?
| | Mutation | 2 | 2019 | 4093 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2026 | 1210 | 0.030 |
Why?
| | Toll-Like Receptor 4 | 1 | 2019 | 277 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2024 | 1792 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2024 | 1468 | 0.030 |
Why?
| | Cromolyn Sodium | 1 | 2016 | 6 | 0.030 |
Why?
| | Stroke | 1 | 2026 | 1287 | 0.030 |
Why?
| | Placenta | 2 | 2014 | 794 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2018 | 504 | 0.030 |
Why?
| | Mesentery | 1 | 2016 | 44 | 0.030 |
Why?
| | Immunotherapy, Adoptive | 1 | 2020 | 356 | 0.030 |
Why?
| | Rats, Inbred F344 | 1 | 2016 | 266 | 0.030 |
Why?
| | Cell Count | 1 | 2017 | 315 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 429 | 0.030 |
Why?
| | Lymphatic Vessels | 1 | 2016 | 64 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 441 | 0.030 |
Why?
| | Disease Progression | 1 | 2024 | 2867 | 0.030 |
Why?
| | Pentacyclic Triterpenes | 1 | 2015 | 11 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2017 | 324 | 0.030 |
Why?
| | Triterpenes | 1 | 2015 | 27 | 0.030 |
Why?
| | Cohort Studies | 1 | 2026 | 6077 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2018 | 930 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2026 | 2786 | 0.030 |
Why?
| | Borrelia burgdorferi | 1 | 2015 | 21 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 467 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2015 | 290 | 0.030 |
Why?
| | Poly I-C | 1 | 2014 | 58 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2015 | 384 | 0.030 |
Why?
| | Fetal Death | 1 | 2014 | 59 | 0.030 |
Why?
| | Interleukin-17 | 1 | 2015 | 121 | 0.030 |
Why?
| | Antigens, Bacterial | 1 | 2015 | 125 | 0.030 |
Why?
| | Toll-Like Receptor 2 | 1 | 2015 | 125 | 0.030 |
Why?
| | HLA-DR Antigens | 1 | 2015 | 211 | 0.030 |
Why?
| | Caspases | 1 | 2015 | 233 | 0.030 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 82 | 0.020 |
Why?
| | Lipoproteins | 1 | 2015 | 165 | 0.020 |
Why?
| | CD3 Complex | 1 | 2014 | 113 | 0.020 |
Why?
| | CD4 Antigens | 1 | 2014 | 136 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2024 | 17438 | 0.020 |
Why?
| | Necrosis | 1 | 2014 | 243 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2026 | 3926 | 0.020 |
Why?
| | Adherens Junctions | 1 | 2013 | 24 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2020 | 2502 | 0.020 |
Why?
| | Forkhead Transcription Factors | 1 | 2014 | 209 | 0.020 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2013 | 83 | 0.020 |
Why?
| | Caspase Inhibitors | 1 | 2013 | 81 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2012 | 150 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2013 | 404 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2013 | 759 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 1036 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2014 | 1361 | 0.020 |
Why?
| | Cell Communication | 1 | 2013 | 327 | 0.020 |
Why?
| | Birth Weight | 1 | 2014 | 521 | 0.020 |
Why?
| | Down-Regulation | 1 | 2012 | 614 | 0.020 |
Why?
| | Colonic Neoplasms | 1 | 2012 | 259 | 0.020 |
Why?
| | Blotting, Western | 1 | 2012 | 1177 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2010 | 197 | 0.020 |
Why?
| | Cell Separation | 1 | 2010 | 300 | 0.020 |
Why?
| | Chronic Disease | 1 | 2015 | 1827 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1712 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 4340 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2012 | 893 | 0.020 |
Why?
| | Mitochondria | 1 | 2013 | 997 | 0.010 |
Why?
| | Hypertension | 1 | 2013 | 1272 | 0.010 |
Why?
| | Time Factors | 1 | 2014 | 7109 | 0.010 |
Why?
| | Prospective Studies | 1 | 2014 | 8123 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2012 | 2675 | 0.010 |
Why?
|
|
Tobin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|